Teva Ocrelizumab Biosimilar: Pricing Execution Must Compensate for Crowded Anti-CD20 Field and PPMS Evidence Ceiling

Teva Licenses Ocrelizumab Biosimilar Candidate from Polpharma Biologics

Teva Pharmaceutical Industries Ltd. and Polpharma Biologics International AG have entered into a global licensing agreement. Teva gains exclusive worldwide commercialization rights for Polpharma Biologics’ proposed biosimilar to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations, upon regulatory approval. Polpharma Biologics will handle development and manufacturing, while Teva will manage regulatory submissions and commercialization in key markets such as the U.S., Europe, Brazil, Canada, Australia, New Zealand, Israel, and Turkey. This agreement aligns with Teva’s "Pivot to Growth" strategy, expanding its biosimilars pipeline through strategic collaborations and aiming to broaden access to biologic medicines for multiple sclerosis patients.

• Teva Pharmaceutical Industries Ltd. has secured exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), encompassing both intravenous and subcutaneous formulations, pending regulatory approval. Under the terms, Polpharma Biologics retains full responsibility for the biosimilar's development and manufacturing, leveraging its expertise in this area. Teva, with its extensive global commercial footprint and capabilities, will be responsible for all regulatory submissions and, subsequently, the commercialization efforts across major markets worldwide.
• This strategic collaboration is a key component of Teva’s "Pivot to Growth" strategy, specifically aimed at expanding its biosimilars pipeline through external partnerships. The agreement combines Polpharma Biologics' proven development capabilities with Teva's commercial strength, creating a clear pathway to bring this medicine to patients. Both companies emphasize their shared commitment to broadening access to high-quality biologic medicines, thereby promoting the long-term sustainability of healthcare systems by offering more treatment options for multiple sclerosis.
• The biosimilar candidate targets Ocrevus® (ocrelizumab), a humanized monoclonal antibody designed to target CD20-positive B cells, which are implicated in the autoimmune activity of multiple sclerosis. Ocrevus® is indicated for treating relapsing forms of multiple sclerosis and primary progressive multiple sclerosis. The agreement covers both intravenous and subcutaneous formulations, with the subcutaneous version marketed as Ocrevus Zunovo® (ocrelizumab and hyaluronidase-ocsq) in the U.S., highlighting the comprehensive nature of the licensing deal for this critical therapeutic area.

Navigating the CD20-Targeting Landscape in Multiple Sclerosis

Several anti-CD20 monoclonal antibodies sharing ocrelizumab's mechanism of B-cell depletion are currently in clinical development or active investigation for multiple sclerosis. These agents differ in their molecular architecture (humanised, fully human, or chimeric) and epitope binding profiles, but converge on CD20-mediated B-cell depletion as the core therapeutic strategy. The trials span a range of intervention models, from randomised controlled trials to real-world and retrospective studies.

Addressing Unmet Needs in Multiple Sclerosis Treatment

Despite significant advances in the multiple sclerosis (MS) therapeutic landscape over the past two decades, critical unmet needs persist across disease subtypes, treatment response, and long-term patient outcomes. Progressive MS in particular continues to represent the most formidable clinical challenge, with the current therapeutic landscape described as "quite disappointing" and in urgent need of further innovation.

• Progressive MS and neuroprotection gaps: The development of treatments incorporating neuroprotection and remyelination remains the greatest unmet challenge in MS care. While immunomodulatory therapies have demonstrated meaningful reductions in relapse rates in relapsing-remitting MS, they offer limited benefit in progressive disease forms, and complete remission remains elusive despite the breadth of therapeutics developed over recent decades.

• Suboptimal treatment response and adherence: The proportion of relapsing-remitting MS patients not adequately responding to disease-modifying therapy ranges from 7% to 49%. Many disease-modifying and immunosuppressive treatments are associated with limited long-term efficacy, and several adverse effect profiles contribute directly to poor patient adherence and compliance.

• Safety as a determinant of treatment selection: Safety is increasingly a primary driver in treatment decision-making. Agents such as natalizumab and fingolimod carry recognized specific risks and incompletely characterized long-term safety profiles. Even high-efficacy options such as autologous haematopoietic stem-cell transplantation, while improved, retain a mortality risk of 2–3%, limiting broader clinical applicability.

• Persistent healthcare system burden: Despite increased adoption of disease-modifying therapy between 2001 and 2010, MS-related annual hospitalizations rose by 40%. Surrogate markers of disability — including nursing home transfers, urinary tract infections, need for skin debridement, and gastrostomy tube placement — remained unchanged across this period, underscoring the disease's continued and substantial impact on individuals and healthcare systems.

• Translational and evidence gaps: Translating findings from preclinical animal models to the clinical setting remains a recognized limitation, particularly for emerging approaches such as bioactive phytochemicals. Similarly, novel therapeutic strategies — including CAR T cell therapy — face significant logistical complexity and challenges in characterizing therapy-associated toxicities before broader clinical adoption can be established.

• Balancing efficacy and tolerability in treatment switching: The decision to transition established patients from well-characterized therapies to new formulations or agents requires careful weighing of efficacy gains against tolerability risks, with no universally accepted framework to guide such decisions across patient subgroups defined by age, comorbidities, or reproductive considerations.

The Evolving Multiple Sclerosis Treatment Landscape

The multiple sclerosis treatment landscape has undergone substantial transformation over the past five years, driven by a combination of high-efficacy monoclonal antibodies, evolving oral therapies, and a growing evidence base from both randomised trials and real-world cohorts. Anti-CD20 B cell–depleting therapies have emerged as a dominant therapeutic class. Ocrelizumab has demonstrated significant annualised relapse rate (ARR) reductions at 12 and 24 months (p < 0.001), along with meaningful improvements in functional outcomes including the 9-Hole Peg Test and Timed 25-Foot Walk, with patients initiating it as first-line therapy showing greater reductions than those previously exposed to other disease-modifying therapies (DMTs). Ofatumumab, evaluated in a Spanish real-world cohort of 87 patients over a median 22-month follow-up, achieved NEDA-3 in 93.1% of patients, reduced ARR from 0.48 pre-treatment to 0.03 on treatment, and maintained a treatment persistence rate of 95.4%, with sustained CD19 B cell depletion confirmed across all assessments. Ublituximab, assessed over five years of continuous treatment, demonstrated an ARR of approximately one relapse per 50 participant-years in year five, with 92% of continuously treated participants remaining free from confirmed disability progression at 24 weeks. Natalizumab, supported by a 2025 Cochrane review of five RCTs enrolling 3,255 participants, reduced relapse risk (HR 0.47, 95% CI 0.39–0.55), sustained disability progression (HR 0.67, 95% CI 0.52–0.88), and new or enlarging T2 lesions (RR 0.49, 95% CI 0.45–0.53) at two-year follow-up. Alemtuzumab, now approved in over 65 countries for relapsing-remitting MS, demonstrated a 69% reduction in annual relapse rate by year four and EDSS stabilisation or improvement in 81% of patients at two years in a Danish real-world cohort, though its long-term immune-mediated adverse effects continue to warrant multidisciplinary surveillance.

Beyond the high-efficacy agents, cladribine tablets have accumulated meaningful real-world evidence, with a cohort of 1,094 patients showing ARR reduction from 0.91 to 0.04 (p < 0.01), NEDA-3 achievement in 70.2%, and 79% completing the second treatment cycle over a mean follow-up of 25.1 months. Emerging BTK inhibitors, including tolebrutinib — evaluated in the GEMINI phase 3 trial against teriflunomide — have shown a hazard ratio for confirmed disability worsening of 0.71 (95% CI 0.53–0.95), a noteworthy signal given the absence of a significant effect on relapse rate ratio (1.03, 95% CI 0.85–1.25), suggesting potential benefit on disability independent of relapse activity. In the paediatric space, the TERIKIDS phase 3 trial in patients aged 10–17 years found that teriflunomide reduced new or enlarged T2 lesions by 55% (RR 0.45, p = 0.00061) and gadolinium-enhancing lesions by 75% (RR 0.25, p < 0.0001), although no statistically significant difference was observed in time to first confirmed clinical relapse (HR 0.66, p = 0.29). Real-world comparative data from India across 192 treatment-naïve RRMS patients showed no statistically significant differences in EDSS change, relapse rate, or MRI parameters across azathioprine, dimethyl fumarate, interferon beta-1a, and teriflunomide at 24 months, though leukopenia was significantly more frequent with azathioprine (p = 0.025).

A critical structural shift has also occurred in trial design philosophy and treatment strategy. The therapeutic paradigm has moved away from a relapse-prevention–centric framework toward a personalised model that incorporates patient preferences, objective clinical and radiographic findings, and patient-reported burdensome symptoms including fatigue, depression, and cognitive impairment. However, a 2024 systematic assessment of 31 phase III RCTs published after 2010 revealed persistent methodological deficiencies — notably an absence of comorbidity data, unjustified placebo use, inadequate outcome measure design, and near-universal non-compliance in analysis and outcome reporting transparency. An analysis of 282 phase III and IV MS drug trials from 2008 to 2024 found a 25.2% failure rate, with failed trials terminating a mean of 10 months earlier than completed studies; low recruitment (28.2%), undisclosed business decisions (26.8%), and logistical problems (12.7%) were the primary failure drivers. Compounding this, registry analyses confirmed that only 5–28% of real-world MS patients would have met the inclusion criteria of corresponding phase III trials, underscoring a persistent and clinically significant gap between trial populations and the patients who ultimately receive approved therapies.

Ocrevus Biosimilar Deal: Reshaping the MS Treatment Landscape

The landscape of multiple sclerosis treatment is on the cusp of a significant transformation with the impending arrival of a biosimilar to ocrelizumab (Ocrevus). Ocrelizumab has been a cornerstone therapy, uniquely approved for both relapsing and primary progressive forms of MS, demonstrating strong anti-inflammatory effects and the ability to slow disability progression. Its efficacy, coupled with a relatively favorable safety profile compared to some earlier treatments, has made it a benchmark in the field.

This global licensing agreement between Teva and Polpharma Biologics for an ocrelizumab biosimilar, crucially including both intravenous and subcutaneous formulations, signals a strategic move to enhance patient access and introduce greater competition. For patients, this could mean more affordable access to a highly effective B-cell depleting therapy, potentially expanding treatment options in regions where cost has been a barrier. For Teva, it represents a key step in its 'Pivot to Growth' strategy, leveraging the biosimilar market to strengthen its presence in neuroimmunology.

However, the path forward is not without its complexities. Polpharma Biologics must successfully navigate the stringent regulatory processes to demonstrate true bioequivalence for both formulations, a challenging endeavor for complex monoclonal antibodies. Furthermore, while ocrelizumab has a known safety profile, including risks of infections and hypogammaglobulinemia with long-term use, the real-world safety and immunogenicity of the biosimilar will be closely scrutinized. Gaining widespread market acceptance from prescribers and securing favorable reimbursement from payers will also be critical, especially as the anti-CD20 market becomes increasingly crowded with other therapies like ofatumumab and ublituximab. Ultimately, this development holds the promise of broadening the reach of advanced MS treatment, but its success will hinge on robust clinical data, effective market strategies, and sustained confidence from the medical community.